Sanofi-Aventis Korea announces availability of oral Amavan

Published: 2007-05-16 06:57:00
Updated: 2007-05-16 06:57:00
Sanofi-Aventis Korea announces on May 9 the availability of Amavan (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes.

As an adjunct to diet and exercise, Amavan is indicated to improve blood sugar control in patients with type 2 diabetes who are ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.